Michael C. Heinrich, M.D.

Head Shot of Michael Heinrich
click here
503 494-6594

Lab Page: Click here


Dr. Heinrich's research includes both preclinical identification of novel molecular targets and testing of new agents in the laboratory and the clinic. This includes both genomics research using high-throughput gentoyping to identify oncogenic mutations and testing of new compounds in cellular and biochemical assays. Dr. Heinrich’s laboratory is particularly expert in the analysis of inhibitors of oncogenic receptor tyrosine kinases such as KIT, PDGFRA and FLT3.

Summary of Current Research

Additional special interests

Development of novel tyrosine kinase inhibitors for treatment of human cancers

Selected Publications

"Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract," Journal of the American Academy of Dermatology - 2014

"Regorafenib for treatment of advanced gastrointestinal stromal Tumors," Expert Opinion on Pharmacotherapy (Vol: 15, Issue: 4, Page 549-558) - 2014

"BRAF mutant gastrointestinal stromal tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance," Oncotarget (Vol: 4, Issue: 2, Page 310-315) - 2013

"Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia," Molecular Cancer (Vol: 12, Issue: 1, ) - 2013

"Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping," Journal of Molecular Diagnostics (Vol: 15, Issue: 2, Page 171-176) - 2013


OHSU Knight Cancer Institute

Visit Our Site

For Healthcare Professionals


  Email Michael Heinrich

503 494-6594

Memberships & Associations

American Society of Clinical Oncology American Society of Hematology Fellow, American College of Physicians American Association of Cancer Research Alpha Omega Alpha